z-logo
open-access-imgOpen Access
Phase I Clinical Trial with a Novel Altered Peptide Ligand Derived from Human Heat-Shock Protein 60 for Treatment of Rheumatoid Arthritis: Safety, Pharmacokinetics and Preliminary Therapeutic Effects
Author(s) -
Dinorah Prada,
Jorge A. Gómez,
N. Di Lorenzo,
Oreste Corrales,
Ana Cristina Andrade López,
Evelio González Dalmau,
Ania Cabrales,
Yusimy Reyes,
Yuliet Bermudez,
Yisel Avila,
L Dominguez Perez,
Claudio Molinero,
O. Martínez,
Leonardo Oramas Díaz,
Yaysel Minoso,
Yassel Ramos,
Hilda Garay,
Ever Perez,
Matilde López,
Osvaldo Reyes,
Yolanda Cruz,
Alfredo Hernandez,
Cabal Carlos,
Vladimir Besada,
Luis Javier González,
Gabrìel Padrón,
María del Carmen Domínguez Horta
Publication year - 2018
Publication title -
journal of clinical trials
Language(s) - English
Resource type - Journals
ISSN - 2167-0870
DOI - 10.4172/2167-0870.1000339
Subject(s) - rheumatoid arthritis , medicine , pharmacokinetics , clinical trial , heat shock protein , pharmacology , shock (circulatory) , safety profile , peptide , arthritis , bioinformatics , adverse effect , chemistry , biology , biochemistry , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom